UMBRELLIN™ (amoxicillin and clavulanate potassium tablets) TABLETS

Manufacturer
Aspen Veterinary Resources Ltd
Effective date
2022-03-22
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-06-01 02:41:22

Label at a glance#

ProductUMBRELLIN
Active ingredientAMOXICILLIN, CLAVULANATE POTASSIUM
Label structure16 sections

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For use in dogs and cats

SAFE HANDLING WARNING SECTION

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION SECTION

DESCRIPTION: Umbrellin™ Tablets are an orally administered formulation comprised of the broad-spectrum antibiotic amoxicillin trihydrate and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid).

Amoxicillin trihydrate is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative, aerobic and anaerobic microorganisms. It does not resist destruction by β-lactamases; therefore, it is not effective against β-lactamase-producing bacteria. Chemically, it is D (-)-α-amino-p-hydroxybenzyl penicillin trihydrate.

Clavulanic acid, an inhibitor of β-lactamase enzymes, is produced by the fermentation of Streptomyces clavuligerus. Clavulanic acid by itself has only weak antibacterial activity. Chemically, clavulanate potassium is potassium z-(3R,5R)-2-β-hydroxyethylidene clavam-3-carboxylate.

MECHANISM OF ACTION SECTION

ACTIONS: Umbrellin™ Tablets are stable in the presence of gastric acid and are not significantly influenced by gastric or intestinal contents. The 2 components are rapidly absorbed resulting in amoxicillin and clavulanic acid concentrations in serum, urine, and tissues similar to those produced when each is administered alone.

Amoxicillin and clavulanic acid diffuse readily into most body tissues and fluids with the exception of brain and spinal fluid, which amoxicillin penetrates adequately when meninges are inflamed. Most of the amoxicillin is excreted unchanged in the urine. Clavulanic acid’s penetration into spinal fluid is unknown at this time. Approximately 15% of the administered dose of clavulanic acid is excreted in the urine within the first 6 hours.

Umbrellin™ Tablets combine the distinctive properties of a broad-spectrum antibiotic and a β-lactamase inhibitor to effectively extend the antibacterial spectrum of amoxicillin to include β- lactamase producing as well as non-β-lactamase-producing aerobic and anaerobic organisms.

MICROBIOLOGY SECTION

MICROBIOLOGY: Amoxicillin is bactericidal in action and acts through the inhibition of biosynthesis of cell wall mucopeptide of susceptible organisms. The action of clavulanic acid extends the antimicrobial spectrum of amoxicillin to include organisms resistant to amoxicillin and other β-lactam antibiotics. Amoxicillin/clavulanate has been shown to have a wide range of activity which includes β-lactamase-producing strains of both gram-positive and gram-negative aerobes, facultative anaerobes, and obligate anaerobes. Many strains of the following organisms, including β-lactamase-producing strains, isolated from veterinary sources, were found to be susceptible to amoxicillin/ clavulanate in vitro but the clinical significance of this activity has not been demonstrated for some of these organisms in animals.

Aerobic bacteria, including Staphylococcus aureus1 , β-lactamase producing Staphylococcus aureus1 (penicillin resistant), Staphylococcus species1 , Staphylococcus epidermidis, Staphylococcus intermedius, Streptococcus faecalis, Streptococcus species1, Corynebacterium pyogenes, Corynebacterium species, Erysipelothrix rhusiopathiae, Bordetella bronchiseptica, Escherichia coli1, Proteus mirabilis, Proteus species, Enterobacter species, Klebsiella pneumoniae, Salmonella dublin, Salmonella typhimurium, Pasteurella multocida, Pasteurella haemolytica, Pasteurella species1

1 The susceptibility of these organisms has also been demonstrated in in vivo studies.

Studies have demonstrated that both aerobic and anaerobic flora are isolated from gingival cultures of dogs with clinical evidence of peridontal disease. Both gram-positive and gram-negative aerobic and anaerobic subgingival isolates indicate sensitivity to amoxicillin/clavulanic acid during antimicrobial susceptibility testing.

SUSCEPTIBILITY TEST: The recommended quantitative disc susceptibility method (FEDERAL REGISTER 37:20527-29; Bauer AW, Kirby WMM, Sherris JC, et al: Antibiotic susceptibility testing by standardized single disc method. Am J Clin Path 45:493, 1966) utilized 30 mcg Augmentin® (AMC) discs for estimating the susceptibility of bacteria to amoxicillin and clavulanate potassium tablets.

INDICATIONS & USAGE SECTION

INDICATIONS: Umbrellin™ Tablets are indicated in the treatment of:

Dogs: Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non- β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli.

Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria. Umbrellin™ Tablets have been shown to be clinically effective for treating cases of canine periodontal disease.

Cats: Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non- β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., E. coli, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.

Therapy may be initiated with Umbrellin™ Tablets prior to obtaining results from bacteriological and susceptibility studies. A culture should be obtained prior to treatment to determine susceptibility of the organisms to Umbrellin™ Tablets. Following determination of susceptibility results and clinical response to medication, therapy may be reevaluated.

CONTRAINDICATIONS SECTION

CONTRAINDICATIONS: The use of this drug is contraindicated in animals with a history of an allergic reaction to any of the penicillins or cephalosporins.

WARNINGS SECTION

WARNINGS: Safety of use in pregnant or breeding animals has not been determined. Store at controlled room temperature, 68-77°F (20-25°C).

Do not remove from foil strip until ready to use

ADVERSE REACTIONS SECTION

ADVERSE REACTIONS: Umbrellin™ Tablets contain a semisynthetic penicillin (amoxicillin) and has the potential for producing allergic reactions. If an allergic reaction occurs, administer epinephrine and/or steroids.

Post-Approval Experience (July, 2017):
The following adverse events are based on the post-approval adverse drug experience reporting. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a casual relationship to product exposure using these data. The following adverse events reported for dogs and cats are listed in decreasing order of reporting frequency for amoxicillin and clavulanate potassium tablets: Anorexia, lethargy, vomiting and diarrhea.

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact the manufacturer at 1-844-227-6687. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or www.fda.gov/reportanimalae.

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION:

Dogs: The recommended dosage is 6.25 mg/lb of body weight twice a day.

Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5-7 days or for 48 hours after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated.

Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

Cats: The recommended dosage is 62.5 mg twice a day

Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5-7 days or for 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated.

Urinary tract infections may require treatment for 10-14 days or longer. The maximum duration of treatment should not exceed 30 days.

HOW SUPPLIED SECTION

HOW SUPPLIED: Umbrellin™ Tablets in the following strengths are supplied in strip packs. Each carton holds 15 strips with 14 tablets per strip (210 tablets per carton).

Each 62.5-mg tablet contains amoxicillin trihydrate equivalent to 50 mg of amoxicillin activity and 12.5 mg of clavulanic acid as the potassium salt. For use in dogs and cats.

Each 125-mg tablet contains amoxicillin trihydrate equivalent to 100 mg of amoxicillin activity and 25 mg of clavulanic acid as the potassium salt. For use in dogs only.

Each 250-mg tablet contains amoxicillin trihydrate equivalent to 200 mg of amoxicillin activity and 50 mg of clavulanic acid as the potassium salt. For use in dogs only.

Each 375-mg tablet contains amoxicillin trihydrate equivalent to 300 mg of amoxicillin activity and 75 mg of clavulanic acid as the potassium salt. For use in dogs only.

SPL UNCLASSIFIED SECTION

Dispense according to recommendations outlined in Dosage and Administration section.

Augmentin is a trademark owned by GlaxoSmithKline.

Approved by FDA under ANADA # 200-702

Manufactured for:
Aspen Veterinary Resources®, LTD.
Liberty, MO 64068
pivetalvet.com
Rev. 01/22

take-timetake-time

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 46066-111-60

UMBRELLIN™

(amoxicillin and clavulanate potassium tablets)

TABLETS

62.5 mg

For use in dogs and cats

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Each film-coated tablet contains amoxicillin trihydrate equivalent to 50 mg of amoxicillin USP activity and 12.5 mg of clavulanic acid USP as the potassium salt

Approved by FDA under ANADA # 200-702

15 strips 14 tablets each 210 tablets

62 mg Carton.jpg62 mg Carton.jpg

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 46066-112-60

UMBRELLIN™

(amoxicillin and clavulanate potassium tablets)

TABLETS

125 mg

For use in dogs

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Each film-coated tablet contains amoxicillin trihydrate equivalent to 100 mg of amoxicillin USP activity and 25 mg of clavulanic acid USP as the potassium salt

Approved by FDA under ANADA # 200-702

15 strips 14 tablets each 210 tablets

125 mg carton.jpg125 mg carton.jpg

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 46066-113-60

UMBRELLIN™

(amoxicillin and clavulanate potassium tablets)

TABLETS

250 mg

For use in dogs

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Each film-coated tablet contains amoxicillin trihydrate equivalent to 200 mg of amoxicillin USP activity and 50 mg of clavulanic acid USP as the potassium salt

Approved by FDA under ANADA # 200-702

15 strips 14 tablets each 210 tablets

250 mg carton250 mg carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 46066-114-60

UMBRELLIN™

(amoxicillin and clavulanate potassium tablets)

TABLETS

375 mg

For use in dogs

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Each film-coated tablet contains amoxicillin trihydrate equivalent to 300 mg of amoxicillin USP activity and 75 mg of clavulanic acid USP as the potassium salt

Approved by FDA under ANADA # 200-702

375 mg Carton.jpg375 mg Carton.jpg

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2105776amoxicillin 100 MG / clavulanate potassium 25 MG Oral TabletPSN1
1810270amoxicillin 200 MG / clavulanate potassium 50 MG Oral TabletPSN1
1810273amoxicillin 300 MG / clavulanate potassium 75 MG Oral TabletPSN1
1810268amoxicillin 50 MG / clavulanate potassium 12.5 MG Oral TabletPSN1
2598546Umbrellin 125 MG Oral TabletPSN1
2598548Umbrellin 250 MG Oral TabletPSN1
2598550Umbrellin 375 MG Oral TabletPSN1
2598552Umbrellin 62.5 MG Oral TabletPSN1
2598546amoxicillin 100 MG / clavulanate 25 MG Oral Tablet [Umbrellin]SBD1
2598548amoxicillin 200 MG / clavulanate 50 MG Oral Tablet [Umbrellin]SBD1
2598550amoxicillin 300 MG / clavulanate 75 MG Oral Tablet [Umbrellin]SBD1
2598552amoxicillin 50 MG / clavulanate 12.5 MG Oral Tablet [Umbrellin]SBD1
2105776amoxicillin 100 MG / clavulanate 25 MG Oral TabletSCD1
1810270amoxicillin 200 MG / clavulanate 50 MG Oral TabletSCD1
1810273amoxicillin 300 MG / clavulanate 75 MG Oral TabletSCD1
1810268amoxicillin 50 MG / clavulanate 12.5 MG Oral TabletSCD1
2105776amoxicillin (as amoxicillin trihydrate) 100 MG / clavulanic acid (as clavulanate potassium) 25 MG Oral TabletSY1
1810270amoxicillin (as amoxicillin trihydrate) 200 MG / clavulanic acid (as clavulanate potassium) 50 MG Oral TabletSY1
1810273amoxicillin (as amoxicillin trihydrate) 300 MG / clavulanic acid (as clavulanate potassium) 75 MG Oral TabletSY1
1810268amoxicillin (as amoxicillin trihydrate) 50 MG / clavulanic acid (as clavulanate potassium) 12.5 MG Oral TabletSY1
2598546Umbrellin (amoxicillin 100 MG / clavulanate potassium 25 MG) Oral TabletSY1
2598548Umbrellin (amoxicillin 200 MG / clavulanate potassium 50 MG) Oral TabletSY1
2598550Umbrellin (amoxicillin 300 MG / clavulanate potassium 75 MG) Oral TabletSY1
2598552Umbrellin (amoxicillin 50 MG / clavulanate potassium 12.5 MG) Oral TabletSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
AMOXICILLIN ANHYDROUS Pharmacologic Class Indexing4Indexing - Pharmacologic Class20180813
CLAVULANIC ACID Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
502415e5-4ac7-4266-a01a-ef44aa3c028dProduct name720250623
d0f377c9-74d8-e2e3-e06e-4d37534f5c0fProduct name320250620
2ebbc361-d28f-48a9-a286-c1ae09cdaf5cProduct name320230314
2bb254ff-3d7f-4bdb-abf9-476506008c55Product name120230117
f33561b9-47cb-411c-a228-16c62e346cd4Product name120200415
8690a824-4bf8-4d1e-b118-2d6dda86bc04Product name220161206
cf3f1c02-1f32-2322-3314-b70ebbf5610eProduct name120140508
ebb3e917-326a-9e18-0354-a19c9f63a2f3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
46066-111-60UMBRELLIN14 in 1 BLISTER PACKTABLET, COATED141
46066-111-60UMBRELLIN15 in 1 CARTONTABLET, COATED151
46066-112-60UMBRELLIN15 in 1 CARTONTABLET, COATED151
46066-112-60UMBRELLIN14 in 1 BLISTER PACKTABLET, COATED141
46066-113-60UMBRELLIN15 in 1 CARTONTABLET, COATED151
46066-113-60UMBRELLIN14 in 1 BLISTER PACKTABLET, COATED141
46066-114-60UMBRELLIN15 in 1 CARTONTABLET, COATED151
46066-114-60UMBRELLIN14 in 1 BLISTER PACKTABLET, COATED141

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
46066-111UMBRELLIN (AMOXICILLIN AND CLAVULANATE POTASSIUM) TABLET, COATED [ASPEN VETERINARY RESOURCES LTD]12 package rows20220410_79c0e6d2-7f56-4743-ac6d-60b90fb0a6fe.zip
46066-112UMBRELLIN (AMOXICILLIN AND CLAVULANATE POTASSIUM) TABLET, COATED [ASPEN VETERINARY RESOURCES LTD]12 package rows20220410_79c0e6d2-7f56-4743-ac6d-60b90fb0a6fe.zip
46066-113UMBRELLIN (AMOXICILLIN AND CLAVULANATE POTASSIUM) TABLET, COATED [ASPEN VETERINARY RESOURCES LTD]12 package rows20220410_79c0e6d2-7f56-4743-ac6d-60b90fb0a6fe.zip
46066-114UMBRELLIN (AMOXICILLIN AND CLAVULANATE POTASSIUM) TABLET, COATED [ASPEN VETERINARY RESOURCES LTD]12 package rows20220410_79c0e6d2-7f56-4743-ac6d-60b90fb0a6fe.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 12 · 227 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
AmoxicillinAMOXICILLINPD-Rx Pharmaceuticals, Inc.d37f2e3c-01f0-4a81-a46f-1615b82e24992026-11-09Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AMOXICILLINAMOXICILLINRedpharm Drug5f988a71-c189-7200-e063-6294a90a0f372026-11-06Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINPD-Rx Pharmaceuticals, Inc.09660a95-a7b3-4d1f-832c-a4fa7a5b7ddd2026-11-05Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINA-S Medication Solutions1dc5cc5a-59ba-4bc9-b581-cb7b70ce26522026-10-27Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINPD-Rx Pharmaceuticals, Inc.b397d4be-d2ef-419a-98ac-844069c99d562026-10-26Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINREMEDYREPACK INC.82c0c5d1-df2d-4352-bd12-99f955af569e2026-10-19Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINChartwell Governmental & Specialty RX, LLC61a9829b-4792-4caa-b75a-b84812f28d4a2026-10-07Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINREMEDYREPACK INC.1d978882-d938-40cf-96be-59052d9599fe2026-10-06Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AMOXICILLINAMOXICILLINChartwell RX, LLCb07b5ac4-253e-4c83-91c3-3fdc46e91a0f2026-10-06Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AMOXICILLINAMOXICILLINProficient Rx LPa5c323c8-ae13-4eda-a9bf-173a0676bf9d2026-10-01Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINSportpharm LLC9b3ab9ea-caee-4186-9068-43ca527c098d2026-09-29Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINSportpharm LLC26c3694b-d7ef-4068-95d3-4f7a9210e1172026-09-29Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINNorthwind Health Company, LLC4ecf56fe-3e72-713a-e063-6294a90ac3d52026-09-15Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINREMEDYREPACK INC.81fe142e-a163-4632-93fb-7cd8d80c50bd2026-09-15Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINREMEDYREPACK INC.2732a8c7-9e4b-43c9-9712-df4b237ab69c2026-09-15Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINREMEDYREPACK INC.575f97d5-ea44-481f-977d-7a28300b2a5f2026-09-15Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AMOXICILLINAMOXICILLINREMEDYREPACK INC.4adc198e-39d8-4b3e-bfa4-278aaf4064ae2026-09-09Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINREMEDYREPACK INC.b6ea2f81-aee6-4c88-b681-50eb28e80a862026-09-03Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINRedpharm Drug5a79669f-52f7-e8ea-e063-6394a90a93b82026-09-02Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN
AmoxicillinAMOXICILLINREMEDYREPACK INC.f37eb415-77b2-41b0-8d20-64e821e4b05d2026-09-02Warnings, Adverse reactionsName fallback
generic name: AMOXICILLIN

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.